Nephrology Dialysis Transplantation最新文献

筛选
英文 中文
Elevated phosphate levels in CKD - a direct threat for the heart. CKD中磷酸盐水平升高-对心脏的直接威胁。
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-14 DOI: 10.1093/ndt/gfaf001
Isaac Campos, Christian Faul
{"title":"Elevated phosphate levels in CKD - a direct threat for the heart.","authors":"Isaac Campos, Christian Faul","doi":"10.1093/ndt/gfaf001","DOIUrl":"https://doi.org/10.1093/ndt/gfaf001","url":null,"abstract":"<p><p>Elevations in systemic phosphate levels, also called hyperphosphatemia, occur in chronic kidney disease (CKD) and during the normal aging process and are associated with various pathologies, such as cardiovascular injury. Experimental studies suggest that at high serum concentrations, phosphate can induce osteogenic differentiation of vascular smooth muscle cells and contribute to vascular calcification. However, the precise underlying mechanism leading to cardiovascular injury is not well understood. Here we discuss how elevations in extracellular phosphate levels could potentially affect cells and intracellular reactions and functions in general. We then zoom in on the heart to discuss whether hyperphosphatemia can have direct pathologic actions beyond inducing vascular calcification. Furthermore, we discuss myocardial calcification as a pathologic event that has not been described and studied in greater detail, but that seems to occur in the context of hyperphosphatemia-induced pathologic cardiac remodeling, as observed in dialysis patients.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport Syndrome. 甘氨酸替代的外显子位置影响常染色体显性Alport综合征的肾脏存活。
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-14 DOI: 10.1093/ndt/gfaf011
Marie-Sophie Pagniez, Victor Fages, Clémence Gatinois, Romain Larrue, Nicolas Pottier, Timothée Laboux, Rémi Lenain, Olivier Grunewald, Thomas Robert, Claire Rigothier, Laurent Mesnard, François Glowacki
{"title":"Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport Syndrome.","authors":"Marie-Sophie Pagniez, Victor Fages, Clémence Gatinois, Romain Larrue, Nicolas Pottier, Timothée Laboux, Rémi Lenain, Olivier Grunewald, Thomas Robert, Claire Rigothier, Laurent Mesnard, François Glowacki","doi":"10.1093/ndt/gfaf011","DOIUrl":"https://doi.org/10.1093/ndt/gfaf011","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Unlike X-linked or autosomal recessive Alport Syndrome, no clear genotype/phenotype correlation has yet been demonstrated in patients carrying a single variant of COL4A3 or COL4A4.</p><p><strong>Methods: </strong>We carried out a multicenter retrospective study to assess the risk factors involved in renal survival in patients presenting a single pathogenic variant on COL4A3 or COL4A4.</p><p><strong>Results: </strong>97 patients presenting a single pathogenic variant of COL4A3 or COL4A4 were included. The prevalence of end-stage kidney disease (ESKD) during follow-up was 28.7% (median age 47.5 years [IQR, 39.1-55.8]). 23 patients carried a 'severe' mutation (frameshift, stop gain, extensive deletion, impacting splicing), and 60 patients presented a glycine substitution in a collagenous domain. In patients with glycine missense variants, the location of the mutation in the distal exons was associated with worse renal survival with a more pronounced decline in eGFR compared to variants in proximal exons. Conversely, the presence of a severe mutation did not impact renal survival.</p><p><strong>Conclusion: </strong>Our results confirm that ADAS can lead to ESKD. We demonstrated that a glycine substitution involving the distal exons had a negative impact on renal survival in ADAS patients, probably due to a trimerization defect. This could help improve personalized follow-up in ADAS patients with glycine substitution and could be integrated to a future prognostic score to accurately predict renal outcomes.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tissue fibrosis in cardiorenal syndrome: crosstalk between heart and kidneys. 心肾综合征的组织纤维化:心肾间的串扰。
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-13 DOI: 10.1093/ndt/gfaf009
Abhi Dutta, Sanchari Chakraborty, Antara Roy, Anupam Mittal, Trayambak Basak
{"title":"Tissue fibrosis in cardiorenal syndrome: crosstalk between heart and kidneys.","authors":"Abhi Dutta, Sanchari Chakraborty, Antara Roy, Anupam Mittal, Trayambak Basak","doi":"10.1093/ndt/gfaf009","DOIUrl":"https://doi.org/10.1093/ndt/gfaf009","url":null,"abstract":"<p><p>Cardiorenal syndrome (CRS) is represented as an intricate dysfunctional interplay between the heart and kidneys, marked by cardiorenal inflammation and fibrosis. Unlike other organs, the repair process in cardiorenal injury involves a regenerative phase characterized by proliferation and polyploidization, followed by a subsequent pathogenic phase of fibrosis. In CRS, acute or chronic cardiorenal injury leads to hyperactive inflammation and fibrotic remodeling, associated with injury-mediated immune cell (Macrophages, Monocytes, and T-cells) infiltration and myofibroblast activation. An inflammatory to fibrotic transition corresponds with macrophage transition (M1-M2) associated with increased TGF-β response. Chronic inflammation disrupts hemodynamic pathways, leading to imbalanced oxidative stress and the production of cytokines and growth factors that promote fibrotic stimulation, contributing to pathological cardiorenal remodeling. The inflammatory response paves the pre-fibrotic cardiorenal niche and drives subsequent fibrotic remodeling by activated myofibroblasts. A fibrotic cardiorenal response in CRS is characterized by increased and degradation-resistant deposition of extracellular proteins especially fibrillar Collagen -I, -III, -V, and non-fibrillar Collagen-IV by active myofibroblasts. Recent advances in basic research animal models of CRS have advanced the knowledge of cardiorenal fibrosis. However, a significant need for clinical applications, trials, and evaluation is still needed. Circulating biomarkers like procollagen peptides and TGF-β have clinically been associated with cardiorenal fibrosis diagnosis in CRS. Treatments targeting the fibrotic pathways have also shown efficacy in amelioration of cardiorenal fibrosis in preclinical models. Recent combination therapies targeting multiple fibrotic pathways have been shown to offer promising results. Understanding the heterogenic pathological progression and fibrogenesis could identify novel therapeutic approaches for clinical CRS diagnosis and treatment.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stratified medicine for blood pressure targets in type 2 diabetes mellitus. 2型糖尿病患者血压指标的分层药物治疗。
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-13 DOI: 10.1093/ndt/gfaf007
Beatriz Fernandez-Fernandez, Jose M Valdivielso, Liffert Vogt, Pantelis Sarafidis, Alberto Ortiz
{"title":"Stratified medicine for blood pressure targets in type 2 diabetes mellitus.","authors":"Beatriz Fernandez-Fernandez, Jose M Valdivielso, Liffert Vogt, Pantelis Sarafidis, Alberto Ortiz","doi":"10.1093/ndt/gfaf007","DOIUrl":"https://doi.org/10.1093/ndt/gfaf007","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-12/23 Blockers Ustekinumab for the Treatment of ANCA-associated Glomerulonephritis. IL-12/23阻滞剂Ustekinumab治疗anca相关性肾小球肾炎
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-13 DOI: 10.1093/ndt/gfaf005
Jonas Engesser, Christian F Krebs, Ulf Panzer
{"title":"IL-12/23 Blockers Ustekinumab for the Treatment of ANCA-associated Glomerulonephritis.","authors":"Jonas Engesser, Christian F Krebs, Ulf Panzer","doi":"10.1093/ndt/gfaf005","DOIUrl":"https://doi.org/10.1093/ndt/gfaf005","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells. 特司他单抗与CAR - t细胞治疗复发和难治性多发性骨髓瘤急性肾损伤的发生率
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-13 DOI: 10.1093/ndt/gfaf004
Mariam Charkviani, Maria Jose Vargas Brochero, Arjunmohan Mohan, Lisa E Vaughan, Tyler B Sandahl, Andre De Menezes Silva Corrae, Yi Lin, Nelson Leung, Sandra M Herrmann
{"title":"Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells.","authors":"Mariam Charkviani, Maria Jose Vargas Brochero, Arjunmohan Mohan, Lisa E Vaughan, Tyler B Sandahl, Andre De Menezes Silva Corrae, Yi Lin, Nelson Leung, Sandra M Herrmann","doi":"10.1093/ndt/gfaf004","DOIUrl":"https://doi.org/10.1093/ndt/gfaf004","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Teclistamab, a novel bispecific monoclonal antibody targeting CD3 and B-cell maturation antigen (BCMA), and chimeric antigen receptor T-cell (CAR-T) therapy are promising options for treating relapsed/refractory multiple myeloma (MM). However, the rates of acute kidney injury (AKI) associated with teclistamab remain inadequately characterized. This study aims to compare the incidence, severity, and outcomes of AKI between patients receiving teclistamab and CAR-T therapy.</p><p><strong>Methods: </strong>This was a retrospective study involving 64 patients with relapsed/refractory MM treated with either teclistamab or CAR-T therapy. All patients had previously received at least four lines of chemotherapy before being treated with either teclistamab or CAR-T. The primary outcome was the incidence of AKI, and secondary outcomes included AKI severity, kidney recovery rates, and mortality. Kaplan-Meier estimates for AKI-free survival were calculated, and hazard ratios (HRs) for AKI risk were determined using Cox proportional hazards models.</p><p><strong>Results: </strong>Sixty-four patients met inclusion criteria for this study (30 received CAR-T and 34 received teclistamab therapy). Among these patients, 14 AKI events occurred in total (22%), with 10 events (29%) in the teclistamab group and 4 events (13%) in the CAR-T group. AKI-free survival estimates at 180 days after treatment initiation were 68% (95% confidence interval [CI]: 53%-87%) for teclistamab patients and 90% (95% CI: 79%-100%) for CAR-T patients. While patients receiving teclistamab were found to have an increased risk of an AKI event compared to those receiving CAR-T therapy, the results were not statistically significant (HR [95% CI]: 3.38 [0.93-12.31], P = 0.065).</p><p><strong>Conclusions: </strong>This study suggests that patients treated with teclistamab may experience a higher incidence of AKI compared to those receiving CAR-T therapy. However, further research is required to determine whether this increased risk is attributable to disease progression or teclistamab itself. These results highlight the need for close kidney function monitoring in patients receiving teclistamab.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-time monitoring of postfilter calcium in regional citrate anticoagulation for continuous kidney replacement therapy. 持续肾替代治疗中局部柠檬酸抗凝后滤过钙的实时监测。
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-13 DOI: 10.1093/ndt/gfaf006
Zhang Qi, Zhang Beiyi, Yue Zengqi, Sun Chen, Yu Jin, Ding Feng
{"title":"Real-time monitoring of postfilter calcium in regional citrate anticoagulation for continuous kidney replacement therapy.","authors":"Zhang Qi, Zhang Beiyi, Yue Zengqi, Sun Chen, Yu Jin, Ding Feng","doi":"10.1093/ndt/gfaf006","DOIUrl":"https://doi.org/10.1093/ndt/gfaf006","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Future of Glucagon-Like Peptide-1 Receptor Agonists In Cardiovascular-Kidney-Metabolic Diseases. 胰高血糖素样肽-1受体激动剂在心血管-肾脏代谢疾病中的应用前景
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-11 DOI: 10.1093/ndt/gfaf008
Matias Trillini, Trond Geir Jenssen, William Patrick Martin, Enrique Morales
{"title":"The Future of Glucagon-Like Peptide-1 Receptor Agonists In Cardiovascular-Kidney-Metabolic Diseases.","authors":"Matias Trillini, Trond Geir Jenssen, William Patrick Martin, Enrique Morales","doi":"10.1093/ndt/gfaf008","DOIUrl":"https://doi.org/10.1093/ndt/gfaf008","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the risks: protecting privacy in single-cell genomics data. 揭露风险:保护单细胞基因组数据的隐私。
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-11 DOI: 10.1093/ndt/gfaf010
Rafael Kramann, Christoph Kuppe, Valerie Luyckx, Wim van Biesen, Stefanie Steiger
{"title":"Unveiling the risks: protecting privacy in single-cell genomics data.","authors":"Rafael Kramann, Christoph Kuppe, Valerie Luyckx, Wim van Biesen, Stefanie Steiger","doi":"10.1093/ndt/gfaf010","DOIUrl":"https://doi.org/10.1093/ndt/gfaf010","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dent disease: Clinical Practice Recommendations. 凹痕病:临床实践建议。
IF 4.8 2区 医学
Nephrology Dialysis Transplantation Pub Date : 2025-01-10 DOI: 10.1093/ndt/gfaf003
Arend Bökenkamp, Gema Ariceta, Detlef Böckenhauer, Olivier Devuyst, Francesco Emma, David van Bennekom, Elena Levtchenko, John Sayer, Aude Servais, Rosa Vargas, Marcin Zaniew, Larisa Prikhodina
{"title":"Dent disease: Clinical Practice Recommendations.","authors":"Arend Bökenkamp, Gema Ariceta, Detlef Böckenhauer, Olivier Devuyst, Francesco Emma, David van Bennekom, Elena Levtchenko, John Sayer, Aude Servais, Rosa Vargas, Marcin Zaniew, Larisa Prikhodina","doi":"10.1093/ndt/gfaf003","DOIUrl":"https://doi.org/10.1093/ndt/gfaf003","url":null,"abstract":"<p><p>Dent disease is a rare X-linked tubulopathy that is characterized by low-molecular-weight (LMW) proteinuria associated with hypercalciuria, which may lead to nephrolithiasis, nephrocalcinosis, and kidney failure between the 3rd and the 5th decades of life in 30-80% of affected males. The disease is most often associated with various manifestations of proximal tubular dysfunction. Affected individuals may present nephrotic range proteinuria which may be misinterpreted and cause diagnostic delay. Due to its rarity, there is limited evidence to guide diagnosis and management. This clinical practice recommendations summarize the current knowledge on Dent disease and provide guidance for diagnosis and management. The recommendations are based on a systematic search of the literature and were endorsed by a Delphi procedure among stakeholders in the field as well as the respective ERA and ESPN working groups.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信